MedTrace Logo

Intravenous Thrombolysis Registry for Acute Ischemic Stroke in China

NCT03997292 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2019-06-25

No results posted yet for this study

Summary

To analyze the real situation of intravenous thrombolysis in acute ischemic stroke in China

Conditions

Interventions

DRUG

Alteplase

According to 0.6-0.9mg / kg alteplase (maximum can not exceed 90mg), of which 10% intravenous injection, the remaining 60 minutes intravenous infusion.

DRUG

Urokinase

1.2-1.5 million U dissolved in 100ml sodium chloride injection, 30 minutes intravenously.

Sponsors & Collaborators

  • General Hospital of Shenyang Military Region

    lead OTHER

Principal Investigators

  • Huisheng Chen, doctor · Neurology Chief

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-01
Primary Completion
2020-09-01
Completion
2020-09-01
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03997292 on ClinicalTrials.gov